SKShunichi Kato

Shunichi Kato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shunichi Kato has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • Hiromasa Yabe

    Departments of Cell Transplantation and Pediatrics, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    5 shared publications
  • Koji Kato

    Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan

    3 shared publications
  • Miharu Yabe

    Department of Pediatrics, Tokai University School of Medicine, Kanagawa‐ken, Japan

    3 shared publications
  • Chidori Kubota

    Department of Pediatrics, Tokai University School of Medicine, Kanagawa-ken, Japan

    2 shared publications
  • Hiromitsu Takakura

    Departments of Cell Transplantation and Pediatrics, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications
  • Ken Tabuchi

    Department of Pediatrics and Data Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

    2 shared publications

Latest Publications

  • Hematopoietic stem cell transplantation for inborn errors of metabolism: A report from the Research Committee on Transplantation for Inborn Errors of Metabolism of the Japanese Ministry of Health, Labour and Welfare and the Working Group of the Japan Society for Hematopoietic Cell Transplantation

    by Shunichi Kato, Hiromasa Yabe, Hiromitsu Takakura, Hideo Mugishima, Mika Ishige, Akemi Tanaka, Koji Kato, Nao Yoshida, Souichi Adachi, Norio Sakai, et al.

    A total of 216 patients with IEM were treated by allogeneic HSCT in Japan from 1985 until 2010. The results of UCBT have improved, and the OS rate of UCBT (81.9%) was not different from those of RBMT (87.2%) or UBMT (73.9%) in 2000–2010. However, EFS rates in RBMT (73.2%) and UBMT (62.2%) were better than that in UCBT (49.5%), and the difference between RBMT and UCBT was significant (p = 0.01). The EFS rate of patients conditioned by RIC (74.6%) was comparable or slightly better than in those who underwent MAC with irradiation (57.9%) or without irradiation (54.2%) in 2000–2010. A more pronounced trend was observed toward differential EFS for UCBT in 2000–2010: RIC (62.9%), MAC with irradiation (20.0%), and MAC without irradiation (42.1%). The difference between RIC and MAC with irradiation was significant (p < 0.03). In summary, we report a Japanese registry analysis of HSCT for IEM with improving survival in UCBT. The introduction of RIC after 2000 was considered to contribute to this improvement. UCBT could be recommended for those who lack an HLA‐identical sibling donor.


  • Open Access

    A single high‐resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low‐resolution HLA mismatch

    by Shigeo Fuji, Junya Kanda, Shunichi Kato, Kazuhiro Ikegame, Satoko Morishima, Toshihiro Miyamoto, Michihiro Hidaka, Kohmei Kubo, Koichi Miyamura, Mitsuru Tsudo, et al.

    The relative importance of the resolution level of HLA typing has not been fully defined for related donor transplantation. To address this question, we retrospectively evaluated patients who underwent a first related hematopoietic stem cell transplantation (HSCT) from 2000 to 2011 from an HLA high-resolution matched (MRD, n = 2,244), high-resolution 1 locus-mismatched (HR-MMRD, n = 116), or low-resolution 1 locus-mismatched related donor (LR-MMRD, n = 396) in the graft-versus-host direction at three loci (HLA A, B, and DRB1) using the database of the Japan Society for Hematopoietic Cell Transplantation. The median age was 40 years (0–74). The median follow-up duration of surviving patients was 950 days. Although the cumulative incidences of grade III–IV acute graft-versus-host disease (GVHD) in the HR-MMRD and LR-MMRD groups were significantly higher than those in the MRD group (HR-MMRD 19.8%, LR-MMRD 20.4%, and MRD 9.5%), there was no statistically significant difference between the HR-MMRD and LR-MMRD groups (P = 0.65). Although both HR-MMRD and LR-MMRD were significantly associated with an increased risk of non-relapse mortality and a worse overall survival, there was no statistically significant difference between the HR-MMRD and LR-MMRD groups. In conclusion, LR-MM and HR-MM have a similar adverse impact on the outcome in related HSCT. Am. J. Hematol. 90:618–623, 2015.


  • Open Access

    Regulation of cell shape and adhesion by CD34

    by Hiroe Ohnishi, Hiroyuki Sasaki, Yoshihiko Nakamura, Shunichi Kato, Kiyoshi Ando, Hisashi Narimatsu, Kouichi Tachibana

    We previously reported that expression of CD43/leukosialin induces cell rounding and microvillus formation via inhibition of cell adhesion. Here, we found that CD34, a cell surface sialomucin and marker for hematopoietic progenitor cells, also inhibited cell adhesion and induced cell rounding and microvillus formation. Forced expression of CD34-induced cell rounding, microvillus formation, and phosphorylation of ezrin/radixin/moesin (ERM) proteins in HEK293T cells, while inhibiting integrin-mediated cell re-attachment. Furthermore, CD34+ blood cells and KG-1 cells, which express endogenous CD34 on their surface, were spherical in shape, surrounded by microvilli, and non-adherent to substrata. In addition, cleavage of O-sialomucin augmented integrin-mediated cell adhesion of KG-1 cells. These results suggest the involvement of CD34 in the inhibition of integrin-mediated cell adhesion and formation of the cell surface structure. The inhibitory function of CD34 in cell adhesion may affect cell shape organization via phosphorylation of ERM proteins. Cellular structures such as the spherical shape and microvilli of CD34+ cells may also contribute to regulation of cell adhesion.


  • Matched sibling donor stem cell transplantation for Fanconi anemia patients with T‐cell somatic mosaicism

    by Miharu Yabe, Takashi Shimizu, Tsuyoshi Morimoto, Takashi Koike, Hiromitsu Takakura, Hideo Tsukamoto, Kazuo Muroi, Koichi Oshima, Keiko Asami, Minoru Takata, et al.

    Yabe M, Shimizu T, Morimoto T, Koike T, Takakura H, Tsukamoto H, Muroi K, Oshima K, Asami K, Takata M, Yamashita T, Kato S, Yabe H. Matched sibling donor stem cell transplantation for Fanconi anemia patients with T‐cell somatic mosaicism. SCT from HLA‐identical sibling donors is generally associated with an excellent survival in FA patients if performed prior to the development of MDS or leukemia. However, the optimal conditioning regimen has not been defined. We report here our experience with 15 Japanese FA patients who underwent HLA‐matched sibling donor SCT. The aim of this study is to compare radiation‐based conditioning to Flu‐based conditioning for FA patients in a Japanese population where the T‐cell somatic mosaicism is higher than in the Caucasian population. Eight patients (a‐group) received a radiation‐based conditioning (500–600 cGy of thoracoabdominal/TBI) with CY dose modification (20–120 mg/kg), and ATG; two patients exhibited rejection. Seven patients (b‐group) received CY (40 mg/kg), 150–180 mg/m2 of Flu, and ATG. Durable engraftment was demonstrated in all patients. In FA patients, Flu‐based conditioning may allow stable engraftment in matched sibling donor transplantation without radiation, even in patients with T‐cell somatic mosaicism.


    • 1 November 2007
      • Vol. 48  (11) , 1462-9

    [The unification of hematopoietic stem cell transplantation registry in Japan and establishment of the TRUMP system].

    by Yoshiko Atsuta, Ritsuro Suzuki, Ayami Yoshimi, Hisashi Gondo, Junji Tanaka, Akira Hiraoka, Koji Kato, Ken Tabuchi, Masahiro Tsuchida, Yasuo Morishima, et al.

    There are four registries of hematopoietic cell transplant in Japan; the Japan Society for Hematopoietic Cell Transplantation (JSHCT), Japanese Society of Pediatric Hematology, Japan Marrow Donor Program and Japan Cord Blood Bank Network, each playing an important role in society by reporting the number and outcomes of transplantations and contributing new findings obtained from studies on individual topics. However, there have been a number of difficulties with analyzing data in overlapping registries and multiple databases at centers affiliated with each of the four registry organizations. JSHCT was pivotal in orchestrating the computerization and unification of hematopoietic stem cell transplant registries for the purpose of resolving these issues and providing a more accurate awareness of hematopoietic stem cell transplantations performed in Japan. JSHCT played a central role in developing the "Transplant Registry Unified Management Program (TRUMP)" to enable transplant institutes to manage patient information with emphasis on convenience to institutes, safety of patient information, and quality of data management. While enhancing domestic registries, the program seeks to coordinate with other hematopoietic cell transplant registries around the world to contribute to the development of registries throughout Asia.


    • 1 September 2004
      • Vol. 45  (9) , 1048-52

    [Cord blood transplantation supported with ex vivo expanded fraction for a patient with myelodysplastic syndrome and metastatic breast cancer].

    by Masayuki Oki, Kiyoshi Ando, Hikaru Nakajima, Yoshiaki Nakano, Hiroyuki Itagaki, Chie Nakashioya, Shunichi Kato, Tomomitsu Hotta

    Despite the promising outcomes of unrelated cord blood transplantations (UCBT) in pediatric recipients, the major limitation in the widespread use of cord blood (CB) as a source of hematopoietic stem cells (HSC), particularly in adults, is the physiological small number of cells. To overcome this limitation, we developed an ex vivo expansion system for HSC, in which CB CD34+ cells are cultured on feeder cells (HESS-5 cells) in the presence of cytokines (TPO, SCF and Flt3 ligand). A phase I/II clinical trial, approved by our institutional review board, has been started to assess the safety and effectiveness of this system. A 52-year-old woman with metastatic breast cancer and myelodysplastic syndrome (MDS) received a non-myeloablative preparative regimen followed by UCBT. On day 0, 75% of the whole CB and a fraction of CD34 negative cells were transplanted. The remaining 25% of the CB was CD34-selected and expanded on HESS-5 in a non-serum media in the presence of TPO, SCF, and Flt3-L. On day 5, the ex vivo-expanded, CD34+ cells were transplanted. The patient received 1.83 x 10(7)/kg of total nucleated cells and 7.7 X 10(4)/kg of CD34+ cells (expanded and unexpanded). No acute adverse effects were observed after the infusion of the cultured cells. She suffered from pneumonia on day 37, a cerebral hemorrhage on day 48, and died on day 50. Further studies are required to assess the effectiveness of this protocol.

  • Cord Blood Transplantation from Unrelated Donors: A Preliminary Report from the Japanese Cord Blood Bank Network

    by Keiichi Isoyama, Kei Ohnuma, Koji Kato, Tsuneo A. Takahashi, Shunro Kai, Shun-Ichi Kato, Minoko Takanashi, Norihiro Sato, Hiroyuki Sato, Kohichi Kitajima, et al.

    As a source for hematopoietic stem cell transplantation (HSCT), cord blood transplantation from unrelated donors (UCBT) is now considered as an acceptable alternative to patients who need unrelated HSCT. To confirm the findings that mismatched UCBT is feasible, we discussed here the results for 477 patients with hematologic malignancies and non-malignancies who were subjected to UCBT coordinated by the Japanese Cord Blood Bank Network (JCBBN). From February 1997 to October 2001, 411 patients with malignancies and 66 with non-malignancies had UCBT through the cord blood bank in the JCBBN; 311 patients had HLA 0-1 mismatched UCBT; 165, had a 2-4 HLA mismatch. The Kaplan-Meier estimates for 3-year disease-free survival rate (DFS) were 35.2 +/- 2.8% in malignant diseases, and 33.6 +/- 7.2% in patients with non-malignant diseases. The HLA disparity had no effect on DFS, incidence of acute graft-versus-host disease, or engraftment. As reported previously, we also noted the importance of graft cell dose in determining survival in UCBT. Major advantages of UCBT include its rapid availability compared with unrelated donor bone marrow, and tolerance of an HLA mismatch at 2 loci, which will enable extension of the donor pool. This review outlines the latest UCBT progress, with emphasis on practical considerations in HLA-mismatched umbilical cord blood selection.


  • Large-scale isolation of monocyte using newly developed nylon-wool bag for high purity and high yield selections of human CD34 positive peripheral blood stem cells.

    by Yoshihiko Nakamura, Mitsunori Noma, Masako Kidokoro, Nobumasa Kobayashi, Mieko Takei, Noriko Matsumura, Osamu Hyodo, Sadaki Inokuchi, Takehito Mukaiyama, Shunichi Kato

  • Changes in hypothalamic-pituitary function following bone marrow transplantation in children

    by Chidori Kubota, Osamu Shinohara, Tomoyuki Hinohara, Kinya Hattori, Hiromasa Yabe, Miharu Yabe, Shunichi Kato, Iwao Takakura

    Patients who undergo bone marrow transplantation (BMT) frequently experience impaired pituitary function, but precise assessment using repeated provocative tests has not been described. We studied 32 children (16 boys) who had BMT after receiving preparative irradiation. Assessment of pituitary function was performed by infusing insulin, luteinizing hormone-releasing hormone (LHRH), and thyrotropin-releasing hormone (TRH) on several occasions at various intervals during the follow-up period. Serum free thyroxine (FT4) and thyrotropin (TSH) levels tended to be low during the early period following BMT. Serum FT4 concentrations reverted to the low-normal range 1 year after transplant, and eight of 29 patients had subnormal and delayed TSH response to TRH consecutively. No children showed overt hypothyroidism. Basal and peak serum gonadotropin levels in response to LHRH were elevated in the patients who had received transplant around the time of puberty. Leydig cell function assessed by human chorionic gonadotropin test was normal. Three girls experienced menarche, and one male patient fathered a normal boy 7 years after BMT. Pituitary-adrenal function and prolactin secretion were not affected. A high incidence of transient hypothyroidism which did not require replacement therapy and gonadal failure among pubertal children were observed. Shielding of gonads should be attempted, if possible, at the time of preparative irradiation to prevent resultant hypogonadism.


  • Growth and growth hormone secretion in children after bone marrow transplantation

    by Osamu Shinohara, Chidori Kubota, Tomoyuki Hinohara, Kinya Hattori, Hiromasa Yabe, Miharu Yabe, Shunichi Kato

    Long-term sequelae of bone marrow transplantation (BMT) are a major concern among long-term survivors since the procedure has been considerably developed over the past decade. In this study, linear growth and growth hormone (GH) secretion were evaluated in 25 children (14 males and 11 females) with various neoplastic or non-neoplastic hematological disorders who had survived for more than 3 years after BMT. Impaired linear growth after BMT, as defined by a change in height standard deviation score (SDS) by more than -1.0 SD, was observed in 14 patients (56%). Four children showed severe growth suppression with a decrease in SD score by more than 2.0, and 10 exhibited a moderate reduction by between 1.0 and 2.0 SD. A recovery of normal height velocity was observed in those who had received BMT at a younger age. The type of disease, a difference in preconditioning regimen, the presence of chronic graft-versus-host disease or a GH secretory capacity 1 year after BMT were not contributing factors for impaired growth. A serial examination of GH secretion with insulin-induced hypoglycemia demonstrated that poor GH secretion was not necessarily a prerequisite for impaired growth. These results indicate that the secretory status of GH does not predict the future growth pattern of children who received BMT.